CytomX Therapeutics, Inc. (CTMX)
2.61
+0.05
(+1.95%)
USD |
NASDAQ |
Oct 07, 11:26
CytomX Therapeutics Enterprise Value : 232.33M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 232.33M |
| October 05, 2026 | 236.69M |
| October 02, 2026 | 232.33M |
| October 01, 2026 | 247.58M |
| September 30, 2026 | 267.19M |
| September 29, 2026 | 273.73M |
| September 28, 2026 | 260.66M |
| September 25, 2026 | 262.84M |
| September 24, 2026 | 273.73M |
| September 23, 2026 | 280.27M |
| September 22, 2026 | 315.13M |
| September 21, 2026 | 275.91M |
| September 18, 2026 | 275.91M |
| September 17, 2026 | 288.98M |
| September 16, 2026 | 277.00M |
| September 15, 2026 | 260.66M |
| September 14, 2026 | 371.78M |
| September 11, 2026 | 391.40M |
| September 10, 2026 | 404.47M |
| September 09, 2026 | 445.87M |
| September 08, 2026 | 469.84M |
| September 04, 2026 | 482.91M |
| September 03, 2026 | 476.38M |
| September 02, 2026 | 485.09M |
| September 01, 2026 | 474.20M |
| Date | Value |
|---|---|
| August 31, 2026 | 406.65M |
| August 28, 2026 | 373.96M |
| August 27, 2026 | 419.72M |
| August 26, 2026 | 397.93M |
| August 25, 2026 | 408.83M |
| August 24, 2026 | 391.40M |
| August 21, 2026 | 389.22M |
| August 20, 2026 | 391.40M |
| August 19, 2026 | 452.41M |
| August 18, 2026 | 413.19M |
| August 17, 2026 | 426.26M |
| August 14, 2026 | 406.65M |
| August 13, 2026 | 404.47M |
| August 12, 2026 | 434.98M |
| August 11, 2026 | 426.26M |
| August 10, 2026 | 424.08M |
| August 07, 2026 | 428.44M |
| August 06, 2026 | 408.83M |
| August 05, 2026 | 404.47M |
| August 04, 2026 | 397.93M |
| August 03, 2026 | 365.25M |
| July 31, 2026 | 349.99M |
| July 30, 2026 | 389.22M |
| July 29, 2026 | 365.25M |
| July 28, 2026 | 376.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 71.09B |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
| Alnylam Pharmaceuticals, Inc. | 29.63B |
| Savara, Inc. | 812.48M |
| Vericel Corp. | 1.982B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.67M |
| Revenue (Quarterly) | 1.418M |
| Total Expenses (Quarterly) | 22.08M |
| EPS Diluted (Quarterly) | -0.0944 |
| Gross Profit Margin (Quarterly) | 96.69% |
| Profit Margin (Quarterly) | -1.46K% |
| Earnings Yield | -17.51% |
| Normalized Earnings Yield | -17.52 |